시장보고서
상품코드
1469161

혈관육종 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 유형별, 치료법별, 최종사용자별, 지역별, 경쟁사별(2019-2029년)

Angiosarcoma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By End user, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 혈관육종 치료 시장 규모는 2023년 2억 7,514만 달러에 달하고, 2029년까지 6.05%의 CAGR로 예측 기간 동안 강력한 성장세를 보일 것으로 예상됩니다. 혈관육종은 혈관에 발생하는 희귀한 침습성 암으로, 의학 연구의 발전, 혁신적인 치료법, 의료진과 일반인의 인식 개선을 촉진하고 있습니다.

의학 및 기술의 끊임없는 발전이 시장 성장의 주요 촉진요인입니다. 혈관육종의 분자 및 유전적 기반을 이해하기 위한 연구자들과 제약회사들의 막대한 투자는 혈관육종 세포와 관련된 유전자 돌연변이 및 신호 전달 경로에 초점을 맞춘 표적 치료로 이어지고 있습니다. 또한, 전 세계적으로 혈관육종의 유병률이 증가하고 있는 것도 시장 확대에 기여하고 있습니다. 드물지만 환경적 요인, 화학제품 노출, 유전적 소인으로 인해 발병률이 증가함에 따라 보다 효과적인 치료법이 요구되고 있습니다. 혈관육종을 포함한 희귀암에 대한 연구비 지원은 눈에 띄게 증가하고 있습니다. 정부, 민간 및 비영리 단체는 연구 이니셔티브에 자원을 할당하여 발견 및 치료법 개발을 가속화하고 있습니다.

MRI, CT 스캔, PET 스캔과 같은 첨단 진단 기술은 혈관육종 진단의 정확성과 신속성을 향상시키고 있습니다. 조기 발견은 성공적인 치료를 위해 매우 중요하며, 이러한 도구는 신속한 개입과 개별화된 치료 전략을 가능하게 합니다. 환자 지원 단체, 의료 기관 및 의료 전문가가 주도하는 인식 개선 캠페인은 시장에 더 많은 영향을 미치고 있습니다. 협력적인 노력으로 혈관육종, 위험 요인, 증상 및 치료법에 대한 인식이 높아지고 있습니다. 혈관육종 치료 시장의 성장은 의학 연구 발전, 자금 지원 증가, 이환율 증가, 진단 방법 개선 및 인식 제고 캠페인에 의해 촉진되고 있습니다. 이러한 요인들은 기술 혁신을 촉진하고 환자 결과를 개선하며 전 세계 혈관육종 환자들에게 희망을 가져다 줄 것입니다. 지속적인 연구 개발 노력은 더 많은 진전을 약속하고 이 문제를 겪고 있는 환자들에게 낙관적인 전망을 가져다 줄 것입니다.

주요 시장 촉진요인

혈관육종의 유병률 증가

인지도 향상 및 조기 발견을 위한 노력

주요 시장 과제

인지도 저하 및 진단 지연

표준화된 치료 프로토콜의 부족

연구 자금 부족

기존 치료법에 대한 내성

주요 시장 동향

표적 치료의 발전

개별화 의료 접근법

면역치료 개발

내성 메커니즘에 대한 연구

부문별 인사이트

치료법별 인사이트

최종사용자별 인사이트

지역별 인사이트

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 혈관육종 치료 세계 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 유형별(혈관육종, 림프관육종, 실질 혈관육종)
    • 치료법별(수술 요법, 방사선 치료, 화학요법, 표적요법, 면역요법, 기타)
    • 최종사용자별(병원·클리닉, 외래 수술 센터, 온라인 약국)
    • 지역별
    • 기업별(2023년)
  • 시장 맵
    • 유형별
    • 치료법별
    • 최종사용자별
    • 지역별

제5장 아시아태평양의 혈관육종 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 유형별
    • 치료법별
    • 최종사용자별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 혈관육종 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 유형별
    • 치료법별
    • 최종사용자별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 혈관육종 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 유형별
    • 치료법별
    • 최종사용자별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 혈관육종 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 유형별
    • 치료법별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 혈관육종 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 유형별
    • 치료법별
    • 최종사용자별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근의 동향
  • 제품 발표
  • 인수합병

제12장 혈관육종 치료 세계 시장 : SWOT 분석

제13장 Porter's Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 능력
  • 고객의 능력
  • 대체품의 위협

제14장 경쟁 상황

  • Novartis AG
  • Bayer AG
  • Sanofi AG
  • Amgen Inc
  • Eli Lilly and Company
  • Genentech Inc.
  • Janssen Global Services, LLC
  • AbbVie Inc
  • Bausch Health Companies Inc.
  • GlaxoSmithKline Plc

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

ksm 24.05.03

Global Angiosarcoma Treatment Marketwas valued at USD 275.14 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.05% through 2029.The Angiosarcoma Treatment Market is witnessing significant growth driven by various factors. Angiosarcoma, a rare and aggressive form of cancer originating in blood vessels, has prompted advancements in medical research, innovative therapies, and increased awareness among healthcare professionals and the public. Continuous advancements in medical science and technology are primary drivers of market growth. Heavy investments by researchers and pharmaceutical firms in understanding angiosarcoma's molecular and genetic basis have led to targeted therapies focusing on genetic mutations and signaling pathways associated with angiosarcoma cells. These precise treatments offer higher efficacy and fewer side effects, enhancing patient quality of life.Also, the rising global prevalence of angiosarcoma cases contributes to market expansion. Though rare, increasing incidence rates driven by environmental factors, chemical exposure, and genetic predisposition necessitate more effective treatments. Research funding dedicated to rare cancers, including angiosarcoma, has increased notably. Governments, private organizations, and non-profits allocate resources for research initiatives, accelerating discoveries and therapeutic developments.

Advanced diagnostic techniques, such as MRI, CT scans, and PET scans, have improved angiosarcoma diagnosis accuracy and timeliness. Early detection is crucial for successful treatment, and these tools enable prompt intervention and personalized treatment strategies. Awareness campaigns led by patient advocacy groups, healthcare organizations, and medical professionals further impact the market. Collaborative efforts raise awareness about angiosarcoma, its risk factors, symptoms, and available treatments. Informed patients are more likely to seek innovative therapies, driving demand for advanced treatments.The Angiosarcoma Treatment Market's growth is propelled by advancements in medical research, increased funding, rising incidence rates, improved diagnostics, and awareness efforts. These factors drive innovation, improve patient outcomes, and offer hope for angiosarcoma patients globally. Continued research and development efforts promise further advancements, providing optimism for individuals battling this challenging disease.

Key Market Drivers

Rising prevalence of angiosarcoma cases

The Angiosarcoma Treatment Market is experiencing significant growth driven by the rising prevalence of angiosarcoma cases, prompting intensified research and development efforts in oncology. Despite being classified as a rare cancer, angiosarcoma's incidence rates have been steadily increasing worldwide. This concerning trend underscores the urgent need for advanced and effective treatment options, spurring investments in research initiatives.

Various factors contribute to the growing number of angiosarcoma cases, including environmental exposures, genetic predisposition, and improved diagnostic techniques leading to more accurate diagnoses. Consequently, there is a pressing demand for accessible and successful treatment modalities.Pharmaceutical and biotechnology sectors are heavily investing in research initiatives focused on angiosarcoma, resulting in the development of targeted therapies, immunotherapies, and personalized treatment approaches. These innovative treatments aim to provide patients with improved outcomes while minimizing side effects, enhancing their quality of life.

Increased awareness among patients, caregivers, and advocacy groups empowers individuals to actively seek advanced treatments and participate in clinical trials, accelerating the adoption of novel therapies. Additionally, collaborations between pharmaceutical companies and patient advocacy organizations streamline the drug development process, ensuring promising treatments reach the market faster and benefit those in need.The escalating prevalence of angiosarcoma cases is driving transformative advancements in the Angiosarcoma Treatment Market. Substantial investments in research are leading to the development of cutting-edge therapies, providing hope to patients and fueling further market expansion.

Growing awareness and early detection efforts

Increasing awareness and early detection initiatives are pivotal drivers in propelling the Angiosarcoma Treatment Market forward, significantly influencing patient outcomes and market dynamics. As awareness about angiosarcoma proliferates among both the general populace and healthcare practitioners, there's a heightened emphasis on timely detection and intervention, leading to more effective treatments.Extensive awareness campaigns spearheaded by patient advocacy groups, healthcare institutions, and medical professionals play a vital role in educating individuals about angiosarcoma, its risk factors, symptoms, and the importance of regular screenings. This heightened public knowledge empowers individuals to recognize potential symptoms early, prompting them to seek medical assistance promptly. Such proactive healthcare-seeking behavior facilitates early diagnoses, enabling swift medical intervention when the disease is at a more manageable stage.

Healthcare professionals benefit from heightened awareness as they become more proficient in identifying subtle signs and symptoms of angiosarcoma. Continuous medical education and awareness initiatives equip doctors to consider angiosarcoma as a potential diagnosis, especially in cases where symptoms may mimic those of other conditions. Early diagnosis not only ensures timely and appropriate treatments for patients but also enhances overall prognosis.Increased awareness instills a sense of urgency among healthcare providers to advocate for regular screenings and encourage at-risk individuals, such as those with a family history of angiosarcoma or exposure to environmental carcinogens, to undergo preventive examinations. These efforts facilitate the identification of pre-cancerous lesions or early-stage tumors, enabling timely interventions and preventing disease progression to advanced stages that are harder to treat.

The synergy of heightened awareness and early detection initiatives in the Angiosarcoma Treatment Market results in improved patient outcomes. By promoting timely diagnoses and proactive healthcare-seeking behavior, these initiatives drive demand for effective treatments, stimulate research and development activities, and ultimately enhance the overall landscape of angiosarcoma treatment options. As awareness continues to expand, it is likely to positively impact the market by ensuring patients receive optimal care and fostering further innovations in the field..

Key Market Challenges

Limited awareness and late diagnosis

Limited awareness and late-stage diagnosis pose significant challenges for the Angiosarcoma Treatment Market. Due to its rarity, angiosarcoma often goes unnoticed, leading to delayed diagnoses at advanced stages. This late-stage detection complicates treatment options, reducing the effectiveness of therapies and worsening patient outcomes. Additionally, the lack of awareness hampers early intervention efforts, hindering timely access to specialized medical care and potentially life-saving treatments. Increasing public and medical professionals' awareness is crucial to promoting early detection, ensuring prompt medical intervention, and improving the overall outlook for angiosarcoma patients.

Lack of standardized treatment protocols

The lack of standardized treatment protocols presents a significant challenge for the Angiosarcoma Treatment Market. With angiosarcoma being a rare and heterogeneous cancer, there is a lack of universally accepted guidelines for its management. This variability in treatment approaches hampers consistency and quality of care across healthcare facilities. Patients may receive different treatments based on individual physician preferences, hindering the establishment of best practices. Standardized protocols are crucial for optimizing treatment outcomes, ensuring uniformity in care, and facilitating meaningful research comparisons. Overcoming this challenge requires collaborative efforts among researchers, clinicians, and regulatory bodies to develop comprehensive, evidence-based guidelines tailored to angiosarcoma's diverse subtypes and stages.

Limited funding for research

Limited funding for research poses a significant challenge for the Angiosarcoma Treatment Market. Due to its rarity, angiosarcoma receives comparatively less research funding than more common cancers. This scarcity of financial resources hampers vital research efforts aimed at understanding the disease's complex biology and developing innovative therapies. Insufficient funding restricts the number of clinical trials, stalling the progress of potential treatments and limiting the exploration of targeted therapies. Overcoming this challenge requires increased investment from both public and private sectors, encouraging collaborative research endeavors to unravel angiosarcoma's mysteries and advance the development of effective, targeted treatments for patients in need.

Resistance to existing therapies

Resistance to existing therapies presents a significant challenge for the Angiosarcoma Treatment Market. As the disease progresses, angiosarcoma cells can develop resistance to commonly used treatments, rendering them ineffective. This phenomenon not only limits the options available to patients but also complicates the development of new therapies. Overcoming resistance requires continuous research to identify the underlying mechanisms and develop innovative drugs that can bypass or overcome resistance pathways. Additionally, personalized treatment approaches tailored to individual patients' genetic profiles may hold the key to addressing resistance issues, emphasizing the need for targeted therapies and precision medicine strategies in the battle against angiosarcoma.

Key Market Trends

Advancements in targeted therapies

Advancements in targeted therapies represent a prominent trend in the Angiosarcoma Treatment Market. Through extensive research, scientists are identifying specific genetic and molecular characteristics of angiosarcoma cells. This knowledge enables the development of therapies precisely tailored to target these unique markers, minimizing damage to healthy cells and reducing side effects. Targeted therapies, such as angiogenesis inhibitors and tyrosine kinase inhibitors, have shown promising results in clinical trials. Their effectiveness in inhibiting the growth of cancer cells while sparing normal tissues marks a paradigm shift in cancer treatment. This trend signifies a more precise and personalized approach, offering new hope for angiosarcoma patients and driving the market towards innovative, patient-specific therapeutic solutions.

Personalized medicine approaches

Personalized medicine approaches have emerged as a pivotal trend in the Angiosarcoma Treatment Market. By analyzing patients' genetic profiles and understanding the specific molecular alterations driving angiosarcoma, clinicians can tailor treatments to individual characteristics. This precision medicine allows for targeted therapies that are more effective and have fewer side effects compared to traditional treatments. Advances in genomic sequencing technologies and data analysis techniques have made personalized treatments increasingly viable. By focusing on the unique genetic makeup of each patient's tumor, personalized medicine is revolutionizing angiosarcoma care, leading to improved outcomes and enhancing the overall landscape of treatment options available to patients. This trend signifies a transformative shift toward more precise, efficient, and patient-centered therapies in the field of angiosarcoma treatment.

Immunotherapies development

Immunotherapies development stands as a promising trend in the Angiosarcoma Treatment Market. Harnessing the body's immune system to combat cancer, immunotherapies have shown remarkable potential in treating various cancers, including angiosarcoma. Approaches like immune checkpoint inhibitors and adoptive cell therapies are being explored, aiming to stimulate the immune response against angiosarcoma cells. These therapies have demonstrated encouraging results in clinical trials, offering new hope for patients resistant to conventional treatments. Ongoing research into immunomodulatory agents and combination therapies further underscores the market's focus on immunotherapies. As these innovative treatments continue to evolve, they represent a transformative trend, ushering in a new era of effective and targeted angiosarcoma treatments.

Research on resistance mechanisms

Research on resistance mechanisms has become a significant trend in the Angiosarcoma Treatment Market. Understanding why certain treatments lose effectiveness over time is crucial for developing innovative therapies. Scientists are delving into the molecular intricacies of angiosarcoma cells to identify resistance mechanisms, enabling the development of strategies to overcome or bypass these challenges. By deciphering these complexities, researchers can design novel drugs and combination therapies, ensuring a more sustained response to treatment. This focused research not only enhances the efficacy of existing therapies but also paves the way for the development of next-generation treatments, offering renewed hope to angiosarcoma patients and driving the market toward innovative solutions.

Segmental Insights

Treatment Insights

Basedon the Treatment, Immunotherapy has emerged as the dominant segment in the Angiosarcoma Treatment Market. This groundbreaking approach harnesses the body's immune system to target and eliminate cancer cells. In the context of angiosarcoma, immunotherapy, particularly immune checkpoint inhibitors and adoptive cell therapies, has shown remarkable efficacy in clinical trials. By bolstering the body's natural defense mechanisms, immunotherapy offers a more targeted and less toxic treatment option compared to conventional therapies. Its success in addressing resistant cases and improving overall survival rates has propelled it to the forefront of angiosarcoma treatments. As research and development in immunotherapy continue to advance, it remains the dominant and promising segment in the market, offering new hope for patients.

End user Insights

Hospitals and clinics have emerged as the dominant segment in the Angiosarcoma Treatment Market. These healthcare facilities serve as the primary points of care, offering comprehensive diagnosis, treatment, and post-treatment support for angiosarcoma patients. Hospitals provide advanced medical infrastructure, specialized equipment, and expert medical professionals, ensuring precise diagnostic procedures and personalized treatment plans. Clinics, on the other hand, often specialize in cancer care, offering tailored therapies and dedicated oncologists. Their role in early detection, administering treatments, and providing follow-up care makes them pivotal in the angiosarcoma treatment landscape. The availability of cutting-edge technologies and multidisciplinary medical teams in hospitals and clinics solidifies their dominance in the market, ensuring patients receive optimal and specialized care.

Regional Insights

North America stands as the dominant region in the Angiosarcoma Treatment Market due to its advanced healthcare infrastructure, robust research and development activities, and a high prevalence of cancer cases. The region hosts renowned medical institutions and research centers, fostering innovation and the development of cutting-edge therapies. Additionally, favorable reimbursement policies and government initiatives promote the adoption of expensive treatments. The region's well-established pharmaceutical industry and collaborations between academia and private sectors further drive advancements in angiosarcoma treatments. Moreover, increasing awareness, early detection efforts, and a large patient population contribute to North America's dominance, making it a hub for pioneering angiosarcoma treatments and research.

Key Market Players

Novartis AG

Bayer AG

Sanofi AG

Amgen Inc

Eli Lilly and Company

Genentech Inc.

Janssen Pharmaceuticals

AbbVie Inc

Bausch Health Companies Inc.

GlaxoSmithKline Plc

Report Scope:

In this report, the Global Angiosarcoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Angiosarcoma Treatment Market,By Type:

  • Hemangiosarcoma
  • Lymphangiosarcoma
  • Parenchymal Angiosarcoma

Angiosarcoma Treatment Market,By Treatment:

  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others

Angiosarcoma Treatment Market,By End user:

  • Hospital Clinics
  • Ambulatory Surgical Centers
  • Online Pharmacies

Angiosarcoma Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Angiosarcoma Treatment Market.

Available Customizations:

Global Angiosarcoma Treatment marketreport with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Angiosarcoma Treatment Market Outlook

  • 4.1.Market Size Forecast
    • 4.1.1.By Value
  • 4.2.Market Share Forecast
    • 4.2.1.By Type (Hemangiosarcoma, Lymphangiosarcoma, Parenchymal Angiosarcoma)
    • 4.2.2.By Treatment (Surgery, Radiotherapy, Chemotherapy, Targeted Therapy, Immunotherapy, Others)
    • 4.2.3.By End user (Hospital Clinics, Ambulatory Surgical Centers, Online Pharmacies)
    • 4.2.4.By Region
    • 4.2.5.By Company (2023)
  • 4.3.Market Map
    • 4.3.1.By Type
    • 4.3.2.By Treatment
    • 4.3.3.By End user
    • 4.3.4.By Region

5.Asia Pacific Angiosarcoma Treatment Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Type
    • 5.2.2.By Treatment
    • 5.2.3.By End user
    • 5.2.4.By Country
  • 5.3.Asia Pacific: Country Analysis
    • 5.3.1.China Angiosarcoma Treatment Market Outlook
      • 5.3.1.1.Market Size Forecast
        • 5.3.1.1.1.By Value
      • 5.3.1.2.Market Share Forecast
        • 5.3.1.2.1.By Type
        • 5.3.1.2.2.By Treatment
        • 5.3.1.2.3.By End user
    • 5.3.2.India Angiosarcoma Treatment Market Outlook
      • 5.3.2.1.Market Size Forecast
        • 5.3.2.1.1.By Value
      • 5.3.2.2.Market Share Forecast
        • 5.3.2.2.1.By Type
        • 5.3.2.2.2.By Treatment
        • 5.3.2.2.3.By End user
    • 5.3.3.Australia Angiosarcoma Treatment Market Outlook
      • 5.3.3.1.Market Size Forecast
        • 5.3.3.1.1.By Value
      • 5.3.3.2.Market Share Forecast
        • 5.3.3.2.1.By Type
        • 5.3.3.2.2.By Treatment
        • 5.3.3.2.3.By End user
    • 5.3.4.Japan Angiosarcoma Treatment Market Outlook
      • 5.3.4.1.Market Size Forecast
        • 5.3.4.1.1.By Value
      • 5.3.4.2.Market Share Forecast
        • 5.3.4.2.1.By Type
        • 5.3.4.2.2.By Treatment
        • 5.3.4.2.3.By End user
    • 5.3.5.South Korea Angiosarcoma Treatment Market Outlook
      • 5.3.5.1.Market Size Forecast
        • 5.3.5.1.1.By Value
      • 5.3.5.2.Market Share Forecast
        • 5.3.5.2.1.By Type
        • 5.3.5.2.2.By Treatment
        • 5.3.5.2.3.By End user

6.Europe Angiosarcoma Treatment Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Type
    • 6.2.2.By Treatment
    • 6.2.3.By End user
    • 6.2.4.By Country
  • 6.3.Europe: Country Analysis
    • 6.3.1.France Angiosarcoma Treatment Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Type
        • 6.3.1.2.2.By Treatment
        • 6.3.1.2.3.By End user
    • 6.3.2.Germany Angiosarcoma Treatment Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Type
        • 6.3.2.2.2.By Treatment
        • 6.3.2.2.3.By End user
    • 6.3.3.Spain Angiosarcoma Treatment Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Type
        • 6.3.3.2.2.By Treatment
        • 6.3.3.2.3.By End user
    • 6.3.4.Italy Angiosarcoma Treatment Market Outlook
      • 6.3.4.1.Market Size Forecast
        • 6.3.4.1.1.By Value
      • 6.3.4.2.Market Share Forecast
        • 6.3.4.2.1.By Type
        • 6.3.4.2.2.By Treatment
        • 6.3.4.2.3.By End user
    • 6.3.5.United Kingdom Angiosarcoma Treatment Market Outlook
      • 6.3.5.1.Market Size Forecast
        • 6.3.5.1.1.By Value
      • 6.3.5.2.Market Share Forecast
        • 6.3.5.2.1.By Type
        • 6.3.5.2.2.By Treatment
        • 6.3.5.2.3.By End user

7.North America Angiosarcoma Treatment Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Type
    • 7.2.2.By Treatment
    • 7.2.3.By End user
    • 7.2.4.By Country
  • 7.3.North America: Country Analysis
    • 7.3.1.United States Angiosarcoma Treatment Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Type
        • 7.3.1.2.2.By Treatment
        • 7.3.1.2.3.By End user
    • 7.3.2.Mexico Angiosarcoma Treatment Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Type
        • 7.3.2.2.2.By Treatment
        • 7.3.2.2.3.By End user
    • 7.3.3.Canada Angiosarcoma Treatment Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Type
        • 7.3.3.2.2.By Treatment
        • 7.3.3.2.3.By End user

8.South America Angiosarcoma Treatment Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Type
    • 8.2.2.By Treatment
    • 8.2.3.By End user
    • 8.2.4.By Country
  • 8.3.South America: Country Analysis
    • 8.3.1.Brazil Angiosarcoma Treatment Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Type
        • 8.3.1.2.2.By Treatment
        • 8.3.1.2.3.By End user
    • 8.3.2.Argentina Angiosarcoma Treatment Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Type
        • 8.3.2.2.2.By Treatment
        • 8.3.2.2.3.By End user
    • 8.3.3.Colombia Angiosarcoma Treatment Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Type
        • 8.3.3.2.2.By Treatment
        • 8.3.3.2.3.By End user

9.Middle East and Africa Angiosarcoma Treatment Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Type
    • 9.2.2.By Treatment
    • 9.2.3.By End user
    • 9.2.4.By Country
  • 9.3.MEA: Country Analysis
    • 9.3.1.South Africa Angiosarcoma Treatment Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Type
        • 9.3.1.2.2.By Treatment
        • 9.3.1.2.3.By End user
    • 9.3.2.Saudi Arabia Angiosarcoma Treatment Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Type
        • 9.3.2.2.2.By Treatment
        • 9.3.2.2.3.By End user
    • 9.3.3.UAE Angiosarcoma Treatment Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Type
        • 9.3.3.2.2.By Treatment
        • 9.3.3.2.3.By End user

10.Market Dynamics

  • 10.1.Drivers
  • 10.2.Challenges

11.Market Trends Developments

  • 11.1.Recent Developments
  • 11.2.Product Launches
  • 11.3.Mergers Acquisitions

12.Global Angiosarcoma Treatment Market: SWOT Analysis

13.Porter's Five Forces Analysis

  • 13.1.Competition in the Industry
  • 13.2.Potential of New Entrants
  • 13.3.Power of Suppliers
  • 13.4.Power of Customers
  • 13.5.Threat of Substitute Product

14.Competitive Landscape

  • 14.1.Novartis AG
    • 14.1.1.Business Overview
    • 14.1.2.Company Snapshot
    • 14.1.3.Product Services
    • 14.1.4.Financials (In case of listed)
    • 14.1.5.Recent Developments
    • 14.1.6.SWOT Analysis
  • 14.2.Bayer AG
  • 14.3.Sanofi AG
  • 14.4.Amgen Inc
  • 14.5.Eli Lilly and Company
  • 14.6.Genentech Inc.
  • 14.7.Janssen Global Services, LLC
  • 14.8.AbbVie Inc
  • 14.9.Bausch Health Companies Inc.
  • 14.10.GlaxoSmithKline Plc

15.Strategic Recommendations

16.About Us Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제